Switch theme
Sign up to access all valuation multiples
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
2020
13.5K+
LTM Revenue $5.0B
LTM EBITDA $874M
$8.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bausch & Lomb has a last 12-month revenue (LTM) of $5.0B and a last 12-month EBITDA of $874M.
In the most recent fiscal year, Bausch & Lomb achieved revenue of $3.5B and an EBITDA of $434M.
Bausch & Lomb expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bausch & Lomb valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.0B | XXX | $3.5B | XXX | XXX | XXX |
| Gross Profit | $3.1B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $874M | XXX | $434M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $631M | XXX | $149M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $198M | XXX | -$229M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | -7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bausch & Lomb's stock price is CAD 16 (or $11).
Bausch & Lomb has current market cap of CAD 5.5B (or $4.0B), and EV of CAD 11.9B (or $8.6B).
See Bausch & Lomb trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.6B | $4.0B | XXX | XXX | XXX | XXX | $0.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bausch & Lomb has market cap of $4.0B and EV of $8.6B.
Bausch & Lomb's trades at 2.5x EV/Revenue multiple, and 19.8x EV/EBITDA.
Equity research analysts estimate Bausch & Lomb's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bausch & Lomb has a P/E ratio of 20.0x.
See valuation multiples for Bausch & Lomb and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| EV (current) | $8.6B | XXX | $8.6B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 9.8x | XXX | 19.8x | XXX | XXX | XXX |
| EV/EBIT | 13.6x | XXX | 57.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.0x | XXX | -17.3x | XXX | XXX | XXX |
| EV/FCF | 43.0x | XXX | -201.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBausch & Lomb's last 12 month revenue growth is 3%
Bausch & Lomb's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Bausch & Lomb's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bausch & Lomb's rule of X is 24% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bausch & Lomb and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | 52% | XXX | XXX | XXX |
| Rule of 40 | 15% | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bausch & Lomb acquired XXX companies to date.
Last acquisition by Bausch & Lomb was XXXXXXXX, XXXXX XXXXX XXXXXX . Bausch & Lomb acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bausch & Lomb founded? | Bausch & Lomb was founded in 2020. |
| Where is Bausch & Lomb headquartered? | Bausch & Lomb is headquartered in Canada. |
| How many employees does Bausch & Lomb have? | As of today, Bausch & Lomb has 13.5K+ employees. |
| Who is the CEO of Bausch & Lomb? | Bausch & Lomb's CEO is Mr. Brenton L. Saunders. |
| Is Bausch & Lomb publicy listed? | Yes, Bausch & Lomb is a public company listed on TSE. |
| What is the stock symbol of Bausch & Lomb? | Bausch & Lomb trades under BLCO ticker. |
| When did Bausch & Lomb go public? | Bausch & Lomb went public in 2022. |
| Who are competitors of Bausch & Lomb? | Similar companies to Bausch & Lomb include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bausch & Lomb? | Bausch & Lomb's current market cap is $4.0B |
| What is the current revenue of Bausch & Lomb? | Bausch & Lomb's last 12 months revenue is $5.0B. |
| What is the current revenue growth of Bausch & Lomb? | Bausch & Lomb revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Bausch & Lomb? | Current revenue multiple of Bausch & Lomb is 1.7x. |
| Is Bausch & Lomb profitable? | Yes, Bausch & Lomb is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bausch & Lomb? | Bausch & Lomb's last 12 months EBITDA is $874M. |
| What is Bausch & Lomb's EBITDA margin? | Bausch & Lomb's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Bausch & Lomb? | Current EBITDA multiple of Bausch & Lomb is 9.8x. |
| What is the current FCF of Bausch & Lomb? | Bausch & Lomb's last 12 months FCF is $200M. |
| What is Bausch & Lomb's FCF margin? | Bausch & Lomb's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Bausch & Lomb? | Current FCF multiple of Bausch & Lomb is 43.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
